Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 10, 2012, Pages 1335-1343

  Kurbatova, Ekaterina ^a   Gammino, V M ^a   Bayona, J ^b,c   Becerra, M C ^b,c   Danilovitz, M ^d   Falzon, D ^e   Gelmanova, I ^b   Keshavjee, S ^b,c   Leimane, V ^f   Mitnick, C D ^b,c   Quelapio, M I ^g   Riekstina, V ^f   Taylor, A ^a   Viiklepp, P ^h   Zignol, M ^e   Cegielski, J P ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b PARTNERS IN HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TARTU UNIVERSITY HOSPITAL   (Estonia)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f Infectology Center of Latvia   (Latvia)

^g Tropical Disease Foundation   (Philippines)

^h NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

Author keywords

MDR TB; Predictive values; Time to culture conversion

Indexed keywords

ISONIAZID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; THIOAMIDE;

ADULT; AGED; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; SPUTUM CULTURE CONVERSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84866447274     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0811     Document Type: Article

References (32)

1. Francis J Curry National Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. San Francisco, CA, USA: Francis J Curry National Tuberculosis Center, 2008.
2. Wallis R S, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-1937.
3. Wallis R S, Doherty T M, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2009; 9: 162-172.
4. Horne D J, Johnson C O, Oren E, Spitters C, Narita M. How soon should patients with smear-positive tuberculosis be released from inpatient isolation? Infect Control Hosp Epidemiol 2010; 31: 78-84.
5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update. WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.
6. Chan E D, Laurel V, Strand M J, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109. (Pubitemid 38624789)
7. Goble M, Iseman M D, Madsen L A, Waite D, Ackerson L, Horsburgh C R Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-532. (Pubitemid 23053828)
8. Shah N S, Pratt R, Armstrong L, Robison V, Castro K G, Cegielski J P. Extensively drug-resistant tuberculosis in the United States, 1993-2007. JAMA 2008; 300: 2153-2160.
9. Gammino V M, Taylor A B, Rich M L, et al. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects. Int J Tuberc Lung Dis 2011; 15: 1315-1322.
10. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med 2000; 161 (4 Pt 1): 1376-1395.
11. Laserson K F, Thorpe L E, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645. (Pubitemid 40826156)
12. Kleinbaum D G, Klein M. Survival analysis: a self-learning text. New York, NY, USA: Springer-Verlag, 2005.
13. US Food and Drug Administration. Development of drugs to treat multidrug-resistant tuberculosis (MDR-TB). AIDAC Advisory Committee meeting, 3 June 2009. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm161856.htm Accessed July 2012.
14. Holtz T H, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006; 144: 650-659. (Pubitemid 46780649)
15. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009; 4: e6914.
16. Leimane V, Riekstina V, Holtz T H, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 2005; 365: 318-326. (Pubitemid 40139109)
17. Migliori G B, Lange C, Girardi E, et al. FQs: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008; 31: 904-905.
18. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345: 170-174. (Pubitemid 32662125)
19. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, Murray M B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
20. Subhash H S, Ashwin I, Jesudason M V, et al. Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: a retrospective study. Indian J Chest Dis Allied Sci 2003; 45: 97-103.
21. Yew W W, Chan C K, Leung C C, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481. (Pubitemid 37290060)
22. Wang J-Y, Wang J-T, Tsai T-H, et al. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int J Tuberc Lung Dis 2010; 14: 65-71.
23. Telzak E E, Fazal B A, Turett G S, Justman J E, Blum S. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1998; 26: 775-776. (Pubitemid 28155051)
24. Domínguez-Castellano A, Muniain M A, Rodriguez-Baño J, et al. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2003; 7: 432-438. (Pubitemid 36565412)
25. Guler M, Unsal E, Dursun B, Aydln O, Capan N. Factors influencing sputum smear and culture conversion time among patients with new case pulmonary tuberculosis. Int J Clin Pract 2007; 61: 231-235.
26. Fortun J, Martin-Davila P, Molina A, et al. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J Antimicrob Chemother 2007; 59: 794-798. (Pubitemid 47073422)
27. Gelmanova I Y, Keshavjee S, Golubchikova V T, et al. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bull World Health Organ 2007; 85: 703-711. (Pubitemid 47416722)
28. Jakubowiak W M, Bogorodskaya E M, Borisov E S, Danilova D I, Kourbatova E K. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions. Int J Tuberc Lung Dis 2007; 11: 46-53. (Pubitemid 46101845)
29. Fleming M F, Krupitsky E, Tsoy M, et al. Alcohol and drug use disorders, HIV status and drug resistance in a sample of Russian TB patients. Int J Tuberc Lung Dis 2006; 10: 565-570. (Pubitemid 43667647)
30. Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med 2009; 150: 766-775.
31. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis 2006; 10: 402-408.
32. Lienhardt C, Davies G. Methodological issues in the design of clinical trials for the treatment of multidrug-resistant tuberculosis: challenges and opportunities. Int J Tuberc Lung Dis 2010; 14: 528-537.